Bardoxolone methyl + Placebo

Phase 3Terminated
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Kidney Disease

Conditions

Diabetic Kidney Disease

Trial Timeline

May 30, 2018 → Jul 31, 2023

About Bardoxolone methyl + Placebo

Bardoxolone methyl + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Diabetic Kidney Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03550443. Target conditions include Diabetic Kidney Disease.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Kidney Disease were approved

Approved (20) Terminated (3) Active (0)

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04018339Phase 1Completed
NCT03550443Phase 3Terminated

Competing Products

20 competing products in Diabetic Kidney Disease

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CHF6467 activeComac MedicalPhase 1/2
22
Ruboxistaurin mesylateEli LillyPhase 3
40
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
Baricitinib + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
Anplag(Sarpogrelate) + PlaceboYuhanApproved
43
CS-3150 + placeboDaiichi SankyoPhase 2
35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
40
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Beraprost sodiumAstellas PharmaPre-clinical
22